X
EXICURE, INC.
XCURCIK 0001698530NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$0
Net Income
$-4.95M
Total Assets
$14.04M
Equity
$3.93M
Shares Out
6.37M
Op. Cash Flow
$-8.55M
Business
Exicure, Inc. is a biotechnology-derived company that historically developed nucleic acid therapies and now focuses on monetizing prior assets while pursuing strategic alternatives. It provides intellectual property, patent licenses and potential royalty streams from its spherical nucleic acid platform and related therapeutic programs. Its activities center on legacy biotech assets (largely divested), licensing and collaboration arrangements, and corporate transactions such as acquisitions and partnerships. The company pursues transactions and collaborations domestically and in Asia, using licensing and partner arrangements as primary distribution channels.
Summary from filing dated 2025-03-18
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 500,000 | 0 | — | — | |
| Total revenue | 0 | 500,000 | 0 | 29 | −483,000 | |
| Research and development expense | 3 | 0 | 1 | 20 | 49 | |
| General and administrative expense | 7 | 5 | 12 | 11 | 13 | |
| Litigation legal expense | 0 | 2 | 938,000 | — | — | |
| Right-of-use asset impairment loss | 0 | 6 | 0 | — | — | |
| Loss from sale of property and equipment | 90,000 | 0 | — | — | — | |
| Gain on early lease termination | −6 | 0 | — | — | — | |
| Total operating expenses | 4 | 13 | 15 | 31 | 62 | |
| Operating loss | −4 | −12 | −15 | −2 | −63 | |
| Dividend income | 107,000 | 5,000 | 52,000 | 78,000 | 8,000 | |
| Interest income | 29,000 | 8,000 | 32,000 | 15,000 | 141,000 | |
| Interest expense | −1,000 | −18,000 | 0 | — | — | |
| Gain on settlement of accounts payables | 346,000 | 407,000 | 0 | — | — | |
| Change in fair value of contingent liability | −2 | 0 | — | — | — | |
| Other income (expense), net | −275,000 | 2 | −2,000 | −40,000 | −11,000 | |
| Total other income (expense), net | −1 | 3 | −2 | −542,000 | −2 | |
| Net loss before provision for income taxes | −6 | −10 | −17 | −2 | −64 | |
| Provision (benefit) for income taxes | −634,000 | 8,000 | 0 | 209,000 | 0 | |
| Net loss | −5 | −10 | −17 | −3 | −64 | |
| Basic loss per common share (in USD per share) | −0.79 | −4.75 | −10.55 | −0.56 | −21.7 | |
| Diluted loss per common share (in USD per share) | −0.79 | −4.75 | −10.55 | −0.56 | −21.7 | |
| Weighted-average basic common shares outstanding (in shares) | 6 | 2 | 2 | 5 | 3 | |
| Weighted-average diluted common shares outstanding (in shares) | 6 | 2 | 2 | 5 | 3 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash, cash equivalents and restricted cash | 4 | 13 | 816,000 | — | — | |
| Other receivable | 58,000 | 521,000 | 15,000 | 0 | — | |
| Prepaid expenses and other current assets | 820,000 | 644,000 | 1 | 1 | 5 | |
| Total current assets | 5 | 14 | 2 | 10 | 44 | |
| Other noncurrent assets | 928,000 | 1 | 3 | 3 | 9 | |
| Property and equipment, net | 306,000 | 26,000 | 54,000 | 3 | 4 | |
| Goodwill | 4 | 0 | — | — | — | |
| Intangible asset | 4 | 0 | — | — | — | |
| Total assets | 14 | 15 | 12 | 23 | 65 | |
| Accounts payable | 2 | 1 | 2 | 361,000 | 3 | |
| Accrued expenses and other current liabilities | 2 | 2 | 879,000 | 1 | 6 | |
| Total current liabilities | 4 | 3 | 3 | 2 | 34 | |
| Contingent consideration | 6 | 0 | — | — | — | |
| Deferred tax liability | 423,000 | 0 | — | — | — | |
| Lease liability, noncurrent | 0 | 5 | 6 | 7 | 7 | |
| Total liabilities | 10 | 8 | 9 | 8 | 54 | |
| Commitments and Contingencies (Note 15) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 6,373,893 issued and outstanding, December 31, 2025; 6,026,841 issued and outstanding, December 31, 2024 | 1,000 | 1,000 | 0 | 0 | 0 | |
| Additional paid-in capital | 208 | 206 | 193 | 188 | 181 | |
| Accumulated other comprehensive loss | −2,000 | 0 | 0 | 0 | −2,000 | |
| Accumulated deficit | −204 | −199 | −190 | −173 | −170 | |
| Total stockholders equity | 4 | 7 | 3 | 15 | 11 | |
| Total liabilities and stockholders equity | 14 | 15 | 12 | 23 | 65 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 242,000 | 28,000 | 634,000 | 1 | 1 | |
| Amortization of right-of-use asset | 218,000 | 796,000 | 741,000 | 693,000 | 656,000 | |
| Equity-based compensation | 2,000 | 22,000 | 1 | 1 | 3 | |
| Loss on disposal/sale of subsidiary | 98,000 | 0 | — | — | — | |
| Income tax benefit | −634,000 | 0 | — | — | — | |
| Accounts receivable | 1 | −506,000 | 0 | 0 | 11,000 | |
| Prepaid expenses and other current assets | 39,000 | 977,000 | 733,000 | 3 | −295,000 | |
| Other noncurrent assets | 198,000 | 0 | 38,000 | −2 | 68,000 | |
| Accounts payable | 177,000 | −193,000 | 1 | −3 | 2 | |
| Accrued expenses | −614,000 | 1 | −399,000 | −5 | 3 | |
| Other liabilities | 0 | −827,000 | −728,000 | −637,000 | −555,000 | |
| Net cash used in operating activities | −9 | −3 | −10 | −36 | −35 | |
| Capital expenditures | −1,000 | 0 | 0 | −10,000 | −968,000 | |
| Proceeds from sale of fixed assets | 42,000 | 0 | 922,000 | 205,000 | 0 | |
| Acquisition of GPCR Therapeutics USA Inc. | −2 | 0 | −2 | −1 | −6 | |
| Proceeds from sale of subsidiary | 474,000 | 0 | — | — | — | |
| Cash removed from the sale of KCC | −232,000 | — | — | — | — | |
| Net cash used in by investing activities | −2 | 0 | −1 | 5 | 43 | |
| Proceeds from sale of common stock | 2 | 12 | 5 | 5 | 11 | |
| Proceeds from short term debt | 0 | 1 | 0 | — | — | |
| Net cash provided by financing activities | 2 | 13 | 4 | −3 | 1 | |
| Net (decrease) in cash, cash equivalents, and restricted cash | −9 | 10 | −8 | −34 | 9 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro